Latest Conference Coverage

The chief medical officer of Forge Biologics discussed the potential advantages of the investigational combination therapy approach.

The chief medical officer of Forge Biologics discussed clinical data presented at ESGCT.

Sarnaik discussed several potential areas of innovation on the horizon.

The director of the CCU/ICU at Saint John’s Health Center discussed unmet respiratory treatment needs in the beginning of the COVID-19 pandemic.

Sarnaik discussed the investigational TIL therapy’s potential as an additional option for patients.

CAN-2409 transduces tumor cells with the thymidine kinase gene, sensitizes these cells to valacyclovir, and stimulates patients’ immune response.

Updated data from a first-in-human trial were presented at the SITC 2022 meeting.

The chief of research and immunotherapy at Cedars-Sinai The Angeles Clinic and Research Institute discussed updated data from the phase 2 C-144-01 study of the lifileucel TIL therapy.

A2B530 and A2B694 target CEA and MSLN cells that have HLA loss of heterozygosity.

The CRIPSR-edited neoantigen-specific T cell therapy demonstrated safety and feasibility in the first-in-human PACT-0101 study presented at SITC 2022.

Further analysis will be performed to elucidate which characteristics correlate with optimal cell therapy behavior.

The vice president of Public Policy & Advocacy of the Muscular Dystrophy Association discussed the organization’s work with regulatory members to advance gene therapies towards review and approval.

The vice president of Public Policy & Advocacy of the Muscular Dystrophy Association discussed the organization’s goals and strategies in educating regulatory decision-makers.

Schlechter discussed the potential advantages of TAC01-HER2 over current standards of care.

Schlechter discussed the design of the TACTIC-2 clinical trial for patients with HER2-positive solid tumors.

MRI revealed that participants who achieved sustained or confirmed disability improvement showed significantly less ventricular enlargement at 12 months.

As we learn more about genomics and identify more genes tied to rare disorders, the role of genetic counselors will become even more critical.

The senior vice president of Research & Early Development at Notch Therapeutics discussed the company’s approach to overcoming the drawbacks of autologous cell therapies.

Pam Gavin, executive vice president of NORD, discussed actions the organization is taking to further improve access to advanced care.

The executive director of Hemophilia Foundation Southern California discussed issues with minorities accessing care for rare diseases and strategies to mitigate them.

With so many therapies on the horizon, the clinical and patient communities need to be adequately prepared to support them.

The professor of ophthalmology at the University College London Institute of Ophthalmology discussed the likely rise of gene therapies in inherited retinal diseases.

Participant 3 showed an 89% decrease in NAA in the CSF at 3 months post-treatment.

The chief scientific officer of cell therapy at Poseida Therapeutics discussed the company’s CAR-T and TCR technologies.

The chief medical officer of Triumvira Immunologics discussed the company’s future plans.

All 5 patients on ERT at study start have since been able to withdraw after gene therapy treatment.

Both botaretigene sparoparvovec and JNJ-81201887 were well-tolerated in treated patients, according to data from the 2022 AAO meeting.

The chief executive officer of Abintus Bio discussed the company’s in vivo approach and how it could help expand patient access to cell therapies.